These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19786883)

  • 21. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of direct-to-consumer advertising of hydroxymethylglutaryl coenzyme a reductase inhibitors on attainment of LDL-C goals.
    Bradford WD; Kleit AN; Nietert PJ; Ornstein S
    Clin Ther; 2006 Dec; 28(12):2105-18; discussion 2104. PubMed ID: 17296467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).
    Ballantyne CM; Weiss R; Moccetti T; Vogt A; Eber B; Sosef F; Duffield E;
    Am J Cardiol; 2007 Mar; 99(5):673-80. PubMed ID: 17317370
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study.
    Van Ganse E; Laforest L; Alemao E; Davies G; Gutkin S; Yin D
    Curr Med Res Opin; 2005 Sep; 21(9):1389-99. PubMed ID: 16197657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical use of ezetimibe.
    Cheng AY; Leiter LA
    Can J Clin Pharmacol; 2003; 10 Suppl A():21A-5A. PubMed ID: 14571302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [New results in the management of hypercholesterolemia].
    Sármán B
    Orv Hetil; 2005 Sep; 146(39):1999-2004. PubMed ID: 16265867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
    Athyros VG; Mikhailidis DP; Papageorgiou AA; Symeonidis AN; Daskalopoulou SS; Kakafika AI; Pehlivanidis AN; Bouloukos VI; Langer A;
    Curr Med Res Opin; 2004 Sep; 20(9):1385-92. PubMed ID: 15383187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
    Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Bays HE
    Curr Med Res Opin; 2007 Sep; 23(9):2125-33. PubMed ID: 17655813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study.
    Faergeman O; Hill L; Windler E; Wiklund O; Asmar R; Duffield E; Sosef F;
    Cardiology; 2008; 111(4):219-28. PubMed ID: 18434729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
    Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease.
    Packard C
    Atheroscler Suppl; 2006 Apr; 7(1):21-9. PubMed ID: 16504600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy.
    Wiviott SD; Cannon CP
    Curr Opin Lipidol; 2006 Dec; 17(6):626-30. PubMed ID: 17095906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
    Robinson JG
    Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expanding options with a wider range of rosuvastatin doses.
    Olsson AG
    Clin Ther; 2006 Nov; 28(11):1747-63. PubMed ID: 17212997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study.
    Ducobu J; Claeys M; Commers K; Van Mieghem W; Nachtergaele H; Vandenbroucke M; Deforce J
    Curr Med Res Opin; 2007 Aug; 23(8):1821-7. PubMed ID: 17609019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does aggressive statin therapy offer improved cholesterol-independent benefits compared to conventional statin treatment?
    Gupta S
    Int J Cardiol; 2004 Aug; 96(2):131-9. PubMed ID: 15262025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LDL-C reductions and goal attainment among naive statin users in the Netherlands: real life results.
    Heintjes EM; Hirsch MW; van der Linden MW; O'Donnell JC; Stalenhoef AF; Herings RM
    Curr Med Res Opin; 2008 Aug; 24(8):2241-50. PubMed ID: 18578957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
    Bays HE; Davidson M; Jones MR; Abby SL
    Am J Cardiol; 2006 Apr; 97(8):1198-205. PubMed ID: 16616026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
    Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.